Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Chugai Pharmaceutical CoMEX:4519N 94 Days Inventory is 280.09 as of Mar. 2026, which is 16% above its 10-year median of 242.36. GuruFocus rates MEX:4519N with a GF Score™ of 94/100 and a GF Value™ of MXN873.09. The stock has 1 warning sign investors should review. Among 921 Drug Manufacturers companies, Chugai Pharmaceutical Co ranks worse than 76.33% on this metric.
The historical rank and industry rank for Chugai Pharmaceutical Co's Days Inventory or its related term are showing as below:
MEX:4519N'
s Days Inventory Range Over the Past 10 Years
Min: 192 Med: 242.36 Max: 276.13
Current: 253.48
During the past 13 years, Chugai Pharmaceutical Co's highest Days Inventory was 276.13. The lowest was 192.00. And the median was 242.36.
MEX:4519N's Days Inventory is ranked worse than 76.33% of 921
companies
in the Drug Manufacturers industry
Industry Median: 164.68
vs MEX:4519N: 253.48
Inventory Turnover measures how fast the company turns over its inventory within a year.
Chugai Pharmaceutical Co's Inventory Turnover for the
three
months ended in Mar. 2026 was 0.33.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Chugai Pharmaceutical Co's Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 0.89.
Chugai Pharmaceutical Co (MEX:4519N) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Chugai Pharmaceutical Co's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Chugai Pharmaceutical Co's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Chugai Pharmaceutical Co Days Inventory Related Terms
Chugai Pharmaceutical Co Days Inventory Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:4519N vs LLY, JNJ, ABBV: Days Inventory Comparison
For the Drug Manufacturers - General subindustry, Chugai Pharmaceutical Co's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chugai Pharmaceutical Co Days Inventory vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Chugai Pharmaceutical Co's Days Inventory distribution charts can be found below:
* The bar in red indicates where Chugai Pharmaceutical Co's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chugai Pharmaceutical Co (MEX:4519N) has a Days Inventory of 280.09 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Chugai Pharmaceutical Co and its competitors. This is 16% above median its historical median of 242.36. Over the past decade, Chugai Pharmaceutical Co's Days Inventory has ranged from 192.00 to 276.13. According to the industry distribution chart, Chugai Pharmaceutical Co ranks #703 out of 921 companies in the Drug Manufacturers industry, placing it in the top 76.3%.
Is Chugai Pharmaceutical Co's Days Inventory too high?
Chugai Pharmaceutical Co's current Days Inventory of 280.09 is 16% above median its 10-year median of 242.36. Over the past 10 years, this metric has ranged from a low of 192.00 to a high of 276.13. The Drug Manufacturers industry median Days Inventory is 164.68. Chugai Pharmaceutical Co's value of 280.09 is 70.1% above this industry median. Based on the distribution chart, Chugai Pharmaceutical Co ranks #703 out of 921 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Chugai Pharmaceutical Co has a GF Score™ of 94/100, reflecting its overall financial health beyond just this single metric.
How does Chugai Pharmaceutical Co's Days Inventory compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Chugai Pharmaceutical Co ranks #703 out of 921 companies for Days Inventory. This places Chugai Pharmaceutical Co in the lower half of its industry. The industry median Days Inventory is 164.68. Chugai Pharmaceutical Co's value of 280.09 is 70.1% above this benchmark. Historically, Chugai Pharmaceutical Co's own Days Inventory has ranged from 192.00 to 276.13 over the past decade. While the company's 10-year median is 242.36 vs. the industry median of 164.68, Chugai Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Drug Manufacturers company?
The median Days Inventory among Drug Manufacturers companies is 164.68, based on 921 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Chugai Pharmaceutical Co's current Days Inventory of 280.09 is 70.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Chugai Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median Days Inventory is 164.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Chugai Pharmaceutical Co's current Days Inventory is 280.09, which is 16% above median its own 10-year median of 242.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chugai Pharmaceutical Co stock overvalued right now?
Chugai Pharmaceutical Co (MEX:4519N) has a current Days Inventory of 280.09. The stock's GF Value™ is MXN873.09, compared to a current price of MXN825.61 — trading 5.4% below its estimated fair value. The current Days Inventory is 280.09, which is 16% above median its 10-year median of 242.36 and 70.1% above the Drug Manufacturers industry median of 164.68. Chugai Pharmaceutical Co's overall GF Score™ is 94/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Chugai Pharmaceutical Co (MEX:4519N), the current Days Inventory is 280.09 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Chugai Pharmaceutical Co (MEX:4519N) Overvalued in 2026?
Based on GuruFocus' analysis, Chugai Pharmaceutical Co stock appears to be undervalued.
The current stock price of MXN825.61 is trading 5.4% below its estimated GF Value™ of MXN873.09.
Key valuation signals for MEX:4519N:
Days Inventory: 280.09 (16% above median its 10-year median of 242.36)
GF Value™: MXN873.09 vs. price of MXN825.61 (5.4% below fair value)
Industry Position: 70.1% above the Drug Manufacturers median (#703 of 921)
No single metric tells the full story. See the MEX:4519N stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Chugai Pharmaceutical is a Japanese drug developer and subsidiary of Roche Holding, which owns roughly 60% of the company. Founded in 1925, Chugai deals primarily in the Japanese market, where it generates roughly half of its revenue. It has been the leader in Japan's oncology market for the past decade, largely due to drugs licensed from its parent's portfolio. The company also develops its own innovative medicines. It is an industry leader in antibody technology with several flagship therapies, including Hemlibra (hemophilia), Actemra (rheumatoid arthritis, covid), Foundayo (oral obesity pill), and Nemluvio (atopic dermatitis, prurigo nodularis).
94GF Score
Get the complete analysis for MEX:4519N
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:4519N has been successfully added to your 
